Survey: Americans Want Weight Loss Drugs Despite High Cost

Published

2 years ago

August 7, 2023

admin

Many Americans really want to lose weight and a new poll shows nearly half of adults would be interested in taking a prescription drug to help them do so. Use Our Content

It can be republished for free.

At the same time, enthusiasm dims sharply if the treatment comes as an injection, if it is not covered by insurance, or if the weight is likely to return after discontinuing treatment, a new nationwide KFF poll found.

Those findings display the enthusiasm for a new generation of pricey weight loss drugs hitting the market and illustrate possible stumbling blocks, as users potentially must deal with weekly self-injections, lack of insurance coverage, and the need to continue the medications indefinitely.

For example, interest dropped to 14% when respondents were asked if they would still consider taking prescription medications if they knew they could regain weight after stopping the drugs.

One way to interpret that finding is people want to lose a few pounds but dont want to be on a drug for the rest of their life, said Ashley Kirzinger, KFFs director of survey methodology. The monthly poll reached out to 1,327 U.S. adults.

The U.S. represents a large market for drugmakers who want to sell weight loss prescriptions: An estimated 42% of the population is classified as obese, according to a controversial metric known as BMI, or body mass index. In the KFF poll, 61% said they were currently trying to lose weight, although only 4% were taking a prescription medication to do so.

That gap between the 4% taking any kind of prescription weight loss treatment and the number of Americans deemed overweight or obese is the sweet spot drugmakers are targeting for the new drugs, which include several diabetes treatments repurposed as weight loss drugs.

The drugs have attracted much attention, both in mainstream publications and broadcasts and on social media, where they are often touted by celebrities and other influencers. Demand jumped and supplies have become limited. About 7 in 10 adults had heard at least a little about the new drugs, according to the survey.

The newer treatments include Wegovy, a slightly higher dose of Novo Nordisks diabetes drug Ozempic, and Mounjaro, an Eli Lilly diabetes treatment for which the company is currently seeking FDA approval as a weight loss drug.

Weight loss with these injectable drugs surpasses those of earlier generations of weight loss medications. But they are also costlier than previous drugs. The monthly costs of the drugs set by the drugmakers can range from $900 to more than $1,300.

At, say, a wholesale price tag of $1,350, the tab per person could top $323,000 over 20 years. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

The drugs appear to work by mimicking a hormone that helps decrease appetite.

Still, like all drugs, they come with side effects, which can include nausea, diarrhea, vomiting, and constipation. More serious side effects include the risk of a type of thyroid cancer, inflammation of the pancreas, or low blood sugar. Health officials in Europe are investigating reports that the drugs may result in other side effects like suicidal thoughts.

The KFF survey found that 80% of adults thought insurers should cover the new weight loss drugs for those diagnosed as overweight or obese. Just over half wanted it covered for anyone who wanted to take it. Half would still support insurance coverage even if doing so could increase everyones monthly premiums. Still, 16% of those surveyed said they would be interested in a weight loss prescription even if their insurance did not cover it.

In practice, coverage for the new treatments varies, and private insurers often peg coverage to patients BMI, a ratio of height to weight. Medicare specifically bars coverage for drugs for anorexia, weight loss, or weight gain, although it pays for bariatric surgery.

Unfortunately, a lot of insurers have not caught up to the idea of recognizing obesity as a disease, said Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School.

Employers and insurers must consider the potential costs of covering the drugs for enrollees perhaps for them to use indefinitely against the potential savings associated with losing weight, such as a lower chance of diabetes or joint problems.

Stanford said the drugs are not a miracle cure and do not work for everyone. But for those who benefit, it can be significantly life-altering in a positive way, she said.

Its not surprising, she added, that the drugs may need to be taken long term, as the idea that there is a quick fix doesnt reflect the complexity of obesity as a disease.

While the drugs currently on the market are injectables, some drugmakers are developing oral weight loss drugs, although it is unclear whether the prices will be the same or less than the injectable products.

Still, many experts predict that a lot of money will be spent on weight loss products in the coming years. In a recent report, Morgan Stanley analysts called obesity the new hypertension and predicted industry revenue from U.S. sales of obesity drugs could rise from a current $1.6 billion annually to $31.5 billion by 2030.

Julie Appleby: jappleby@kff.org, @Julie_appleby Related Topics Health Industry Pharmaceuticals Drug Costs KFF Obesity Prescription Drugs Contact Us Submit a Story Tip

Science

NASA’s RASSOR Robot Digs Deep into Moon Mining Future with Successful Test

Published

57 mins ago

June 7, 2025

admin

NASA’s RASSOR Robot Digs Deep into Moon Mining Future with Successful Test

NASA’s RASSOR (Regolith Advanced Surface Systems Operations Robot) was recently tested on simulated lunar soil at Kennedy Space Center’s Granular Mechanics and Regolith Operations LabThe excavator is built to dig and haul Moon-like regolith, preparing technology for sustained lunar missions. On May 27, NASA mechanical engineer Ben Burdess observed RASSOR’s counterrotating bucket drums churn through the soil simulant and carve a three-foot berm. This trial focuses on RASSOR’s digging drums and directly informs development of NASA’s next-generation Moon-mining excavator, the In-Situ Resource Utilization Pilot Excavator (IPEx)

RASSOR’s Counterrotating Drums and Regolith Excavation

According to NASA’s official website, each of RASSOR’s arms carries a bucket drum that spins in the opposite direction of its mate. Engineers note that this opposing rotation gives RASSOR extra traction even in weak gravity. In the Kennedy lab test, those counterrotating drums anchored the robot into the simulant and effectively dug soil – proof that RASSOR can grip and move regolith reliably on the Moon. With that traction, RASSOR can dig, load, haul and dump loose soil.

The collected regolith can then be processed into hydrogen, oxygen and water, resources critical to sustaining astronauts on the Moon. In short, the test showed RASSOR effectively excavating lunar soil simulant while its drum design demonstrated how future machines can operate in the Moon’s low gravity.

Toward the Moon with IPEx Excavator

NASA engineers say this RASSOR test was primarily to check the bucket-drum design slated for the In-Situ Resource Utilization Pilot Excavator (IPEx). RASSOR serves as a prototype for IPEx, which will be far more autonomous and capable.

IPEx is engineered as a combined bulldozer and dump-truck robot that can mine and transport large volumes of lunar soil. Ultimately, IPEx will dig up regolith and feed it into on-site processing units to extract oxygen, water and fuel from the Moon’s soil. Using these local resources is a cornerstone of NASA’s strategy for supporting a sustained human presence on the Moon and eventually Mars.

Science

Europa May Host Life When Sun Becomes Red Giant, Say Cornell Researchers

Published

2 hours ago

June 7, 2025

admin

Europa May Host Life When Sun Becomes Red Giant, Say Cornell Researchers

Life in the solar system may not entirely end when the sun begins its dramatic transformation into a red giant star. Instead, a brief window of potential habitability may open on Europa, Jupiter’s icy moon, according to new research. Scientists now suggest that as the sun expands and its habitable zone shifts outward, Europa could temporarily offer conditions suitable for life, though the opportunity would last only a few hundred million years, fleeting on cosmic timescales, but not insignificant.

Europa May Host Microbial Life for 200 Million Years After Sun Becomes a Red Giant

As per a new study from the Carl Sagan Institute at Cornell University, soon to be published in the Monthly Notices of the Royal Astronomical Society, the red giant sun’s energy output could reach as far as Jupiter’s orbit. While Jupiter itself will remain inhospitable, its moon Europa may receive enough combined heat from both solar radiation and Jupiter’s increased reflection to melt parts of its icy crust. This warming could expose or even evaporate subsurface oceans long believed to exist beneath its frozen shell.

Researchers estimate that Europa’s surface will sublimate significantly on the side facing Jupiter, while equatorial regions will suffer water loss due to convective heat transport. Yet, the northern and southern regions on the side opposite Jupiter might retain more water, creating a modest water-vapour atmosphere. Scientists note that this could preserve the conditions needed to sustain life for as long as 200 million years.

The briefer span of Earth history might have been long enough for microscopic life to flourish or endure, in particular if life thrives somewhere below Europa’s ice. This finding could open new paths for astrobiological investigation, including future telescopes with the capability of fishing for biosignatures on ice-covered moons that orbit red giant stars.

Findings such as the exomoon discovery could open a new chapter in that search, with the possibility that after humans die out or destroy themselves, Europa might be all that remains of life in the solar system.